RPO LLC’s Lexicon Pharmaceuticals LXRX Stock Holding History

RPO LLC’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-44,242	Closed	-$32.7K	–	72
2024 Q4	$32.7K	Buy	+44,242	New	+$53.3K	0.03%	69
2024 Q1	–	Sell	-32,000	Closed	-$49K	–	76
2023 Q4	$49K	Buy	+32,000	New	+$38K	0.07%	79

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RPO LLC's LXRX Position: Q1 2025 in Review

RPO LLC sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 44,242 shares — an estimated $32.7K sold.

RPO LLC first reported a position in LXRX in Q4 2023 and held it in 2 quarters. The position peaked at $49K in Q4 2023. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

RPO LLC reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
RPO LLC sold 44,242 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $32.7K.
RPO LLC first reported a position in Lexicon Pharmaceuticals in Q4 2023 and held it in 2 quarters.
RPO LLC's Lexicon Pharmaceuticals position peaked at $49K in Q4 2023.
127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on RPO LLC's 13F filing for Q1 2025, filed 13 May 2025.